Third-line Treatment of Gefitinib in NSCLC Patients

NCT01933347 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Gefitinib

Sponsor

Guangdong Association of Clinical Trials